Class-action securities suit goes forward against Amgen

A U.S. appeals court will let Amgen ($AMGN) investors keep their class-action status in a complaint accusing the company of failing to fully disclose potential safety problems with its anemia drugs Epogen and Aranesp. The shareholder that originally filed the suit also alleges Amgen promoted significant off-label use of the drugs. Report

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.